On the Covacta trial’s key secondary endpoint of death prevention by week four, a 19.7% death rate among Actemra patients didn't differ from the placebo group’s 19.4%. This marks the second major blow to the theory of targeting inflammatory molecule IL-6 in treating COVID-19. Earlier this month, Sanofi and Regeneron pulled the plug on a phase 3 trial of their rival IL-6 inhibitor Kevzara after finding the drug couldn’t help severely ill COVID-19 patients who were on mechanical ventilation. FiercePharma
Wednesday, July 29, 2020
Roche arthritis drug Actemra flunks COVID-19 study, but remdesivir combo data await
On the Covacta trial’s key secondary endpoint of death prevention by week four, a 19.7% death rate among Actemra patients didn't differ from the placebo group’s 19.4%. This marks the second major blow to the theory of targeting inflammatory molecule IL-6 in treating COVID-19. Earlier this month, Sanofi and Regeneron pulled the plug on a phase 3 trial of their rival IL-6 inhibitor Kevzara after finding the drug couldn’t help severely ill COVID-19 patients who were on mechanical ventilation. FiercePharma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment